OVOlga V. Vorob’еVa

Olga V. Vorob’еVa

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Olga V. Vorob’еVa has a total of 91 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Factors associated with the progression of mild cognitive impairment in patients with atrial fibrillation

    by V.V. Fateeva, N.N. Shindryaeva, O.V. Vorob’EVa

    Objective. To identify factors associated with the progression of vascular moderate cognitive impairment (MCI) over 36 months, based on analyses of clinical, demographic, neuropsychological, laboratory, and neuroimaging characteristics of patients with atrial fibrillation (AF). Material and methods. Data from outpatient visits between 2019 and 2022 were reviewed. Patients with vascular MCI and AF were identified based on the VasCog criteria, neuropsychological assessments using the Montreal Cognitive Assessment (MoCA; scores 18—25), and national and European clinical guidelines. The study used basic statistics, univariate regression, and binary logistic regression to identify and evaluate the predictors of vascular MCI progression in patients with AF after 36 months. Results. Among the 143 patients with vascular MCI and AF (mean age 57.7±6.2 years), 63 patients (n=90) progressed to MCI by 36 months. Several factors associated with a decline in cognitive function were identified: an ischemic stroke occurring 3 to 6 months prior to enrollment (p=0.001), the presence of five or more lacunar infarctions (p=0.005), hypertension classified as grade II or higher (p=0.002), type 2 diabetes mellitus (p=0.002), a C-reactive protein level exceeding 5 mg/L (p=0.019), memory domain scores on the MoCA below 15 points (p=0.004), and scores on the Hospital Anxiety and Depression Scale (HADS-A) of 11 points or lower (p=0.037). Conclusions. The early identification of factors associated with a poor prognosis for MCI at 36 months may reduce vascular dementia burden among patients with AF.

  • Clinical features of chronic pain and premorbid factors in patients with various phenotypes of metabolic syndrome

    by O.V. Vorob’EVa, A.A. Gertsog, G.M. Ashikhmin, T.E. Morozova

    Objective. To identify the clinical features associated with chronic pain and the premorbid factors in patients with metabolic syndrome of various phenotypes. Materials and methods. In this prospective comparative cohort study involving 118 patients with chronic pain, participants were divided into four groups based on the predominant phenotype of their metabolic syndrome: lipocentric (n=41), hypertensive (n=22), mixed (n=18), and control (n=37). We assessed clinical pain characteristics, anthropometric parameters, comorbidities, and behavioral and psychosocial premorbid factors. Results. Patients exhibiting a mixed phenotype of metabolic syndrome demonstrated higher pain intensity (7.5 [6; 8] points on the NRS scale, p=0.003), more pain sites (4 [3; 6], p=0.029), and experienced more frequent (p=0.004) and prolonged exacerbations (p=0.002) compared to the control group. Notably, severe fatigue (FAS scores ³22, p=0.007) was a specific premorbid feature in this group. Additionally, both the hypertensive and mixed phenotypes exhibited a higher prevalence of pain in the lower back and lower extremities. Conclusions. The chronic pain experienced by patients with metabolic syndrome displays phenotype-dependent variations, with the mixed phenotype exhibiting the most unfavorable pain profile. Recognizing the phenotype of metabolic syndrome is essential for personalized evaluation and management of chronic pain in outpatient settings.

  • Open Access

    Boundaries of professional responsibility of a general practitioner (family doctor): results of a Russian national study

    by O. M. Drapkina, V. V. Fomin, T. E. Morozova, A. V. Volnukhin, R. N. Shepel, S. Yu. Astanina, N. L. Shaporova, O. Yu. Kuznetsova, E. A. Gritsaeva, G. N. Shemetova, et al.

    Aim. To define the boundaries of professional responsibility of general practitioners (family physicians) and develop algorithms for their interaction with specialist physicians. Material and methods. Fifty individuals meeting the inclusion criteria, representing 13 Russian regions, were recruited as experts. Expert assessment cards for job functions were developed for 14 areas in which general practitioners (family physicians) practice. It included information on 252 different diseases. Results. It was found that general practitioners (family physicians) can independently manage patients in 9,9% of cases, monitor treatment prescribed by a specialist in 35,7% of cases, refer patients for followup care with a specialist in 40,5% of cases, and hospitalize patients in 13,9% of cases. With regard to internal medicine, the predominant job functions are independent patient management (21,6% of all cases) and monitoring of treatment prescribed by a specialist (52,7%). Other areas of professional activity are primarily related to monitoring treatment prescribed by a specialist or preliminary diagnostics. Conclusion. The obtained results should be taken into account when defining the professional competencies of the educational standard for general practice (family medicine) during next revision, improving educational programs. This should also form the basis for interaction algorithms between general practitioners (family doctors) and specialist physicians.

  • Effect of vitamin D levels on tension headache characteristics: a systematic review

    by O.V. Vorobyeva, T.E. Morozova, A.A. Gertsog, M.V. Gurjar, M.A. Kiriakova, S.V. Sobenina

    Objective. To evaluate the relationship between vitamin D levels and the frequency and intensity of tension headaches, as well as the therapeutic effectiveness of vitamin D. Material and methods. A systematic review of the literature was conducted, including observational and interventional studies on the relationship between vitamin D levels and tension headache characteristics. The review included 8 studies selected from PubMed, ScienceDirect, Google Scholar, eLibrary, and Europe PMC databases that met the inclusion criteria. The study design, clinical parameters of pain, vitamin D levels, and the effect of therapy were assessed. Results. Vitamin D deficiency is associated with a higher incidence and longer duration of headache episodes, but not with increased intensity. Several studies found a significant negative correlation between vitamin D levels and headache frequency or duration. Interventional studies confirmed the clinical benefit of vitamin D therapy in patients with hypovitaminosis. Conclusion. There is strong evidence linking vitamin D deficiency to a more severe course of tension headaches. Assessing and correcting vitamin D levels may be important in comprehensive treatment. However, further randomized controlled trials are needed to confirm causality and establish standardized therapeutic strategies.

  • Open Access

    The cognitive restoration effects of Picamilon® Ginkgo in patients with non-amnestic mild cognitive impairment (results of a comparative cohort study)

    by O. V. Vorob’EVa, V. V. Fateeva, N. N. Shindryaeva

    Introduction . The concept of mild cognitive impairment (MCI) serves as a useful diagnosis for clinicians, enabling careful monitoring and extensive potential for therapeutic interventions. The phenotypic classification of MCI allows to identify the probable cause of MCI and predict its development. Aim . To evaluate the effect of a 12-week (3-month) therapy course with Picamilon® Ginkgo on restoration of cognitive functions in patients with the non-amnestic MCI phenotype. Materials and methods . The treatment group included 21 patients receiving Picamilon® Ginkgo as part of combination therapy. The comparison group included 25 patients receiving only stable combination therapy aimed to manage vascular risks. Cognitive impairment was diagnosed and assessed at baseline and at 12 weeks (3 months) of stable therapy using the MoCA test to determine total MoCA sores (MoCA-Total), MoCA-MIS, and MoCA domain-specific index scores: executive function, attention, and visual-constructive skills. Results . After treatment, the mean MoCA-total score was significantly higher in the group of patients who additionally received Picamilon® Ginkgo as compared to the patients receiving vascular risk reduction therapy alone (26.8 ± 1.1 versus 25.3 ± 1.3 points, p < 0.05). Among patients randomized to Picamilon® Ginkgo group, 47.6% returned back to normal cognitive function (MoCA-total ≥26 points) scores versus 20.0% of patients in the comparison group (χ 2 = 3.962, p < 0.05). Conclusion . The combination agent Picamilon® Ginkgo is an effective, safe, and promising treatment for vascular cognitive impairment, including the potential for reversion to normal cognitive function.

  • Open Access

    Quantitative Evaluation of Respiratory Dysfunction and Its Relationships With Parkinson’s Disease Symptoms

    by A. A. Pilipovich, O. V. Vorob’EVa, S. A. Makarov, N. N. Shindryaeva

    Respiratory disorders significantly impair functional baseline and quality of life (QoL) in Parkinson’s disease (PD). This cross‐sectional study aimed to evaluate spirographic lung function parameters in PD and determine their relationships with motor and nonmotor symptoms, QoL, and dopaminergic therapy. Spirometric parameters were recorded in 57 outpatients with PD and 10 healthy controls. PD patients underwent clinical assessments using UPDRS Parts II and III, Schwab and England scale, PDQ‐39, and PFS‐16. Spirometric analysis revealed significant decreases in VC %pred in PD patients versus controls, and in FVC %pred in PD Stage III versus PD Stage II. Decreased lung function correlated with H&Y stage (VC, FVC, FEV 1 ) and showed inverse correlations with UPDRS Parts II and III scores, most pronounced for axial‐locomotor impairments (posturing, gait, stability, arising from chair) and bradykinesia. PFS‐16 fatigue index inversely correlated with FEV 1 and PEF. Worse QoL (PDQ‐39 summary index, emotional well‐being, and cognition domains) was primarily coupled with decreased expiratory flow rates (FEV 1 , PEF). Untreated PD patients exhibited significantly lower FVC%pred, FEV 1 %pred, FEF 75 %pred, and Tiffeneau index than those on dopaminergic therapy. This study demonstrates the presence of respiratory dysfunction in PD Stages II and III and its negative association with QoL. The results highlight the relationship between lung function decline and overall PD progression, with the strongest associations revealing the most significant contribution of postural abnormalities, bradykinesia, and pathological fatigue. Furthermore, the obtained data suggest a potential compensating role of dopaminergic therapy.

  • Comparative study of the efficacy and safety of combined therapy with lornoxicam (Xefokam Rapid) and a nucleotide complex Xefomielyn in patients with exacerbation of chronic nonspecific low back pain

    by M.L. Kukushkin, Y.V. Karakulova, K.V. Vaitkus, O.B. Doronina, O.V. Vorobeva, K.A. Kolmakova, E.A. Lyakhova

    Objective. To evaluate the efficacy and safety of combined therapy with lornoxicam (Xefokam Rapid) and a nucleotide complex Xefomielyn compared to lornoxicam monotherapy in patients with exacerbation of chronic nonspecific low back pain (CNLBP). Material and methods. The study included 181 patients divided into a monotherapy group Xefokam Rapid and a combined therapy group with the addition of the nucleotide complex Xefomielyn. Pain intensity was assessed using the Numerical Rating Scale, functional status using the Roland—Morris Disability Questionnaire, recurrence rate, and treatment satisfaction. Results. Combination therapy provided a more pronounced reduction in pain intensity, a lower relapse rate, an improvement in functional status and higher satisfaction with treatment compared to monotherapy. Conclusion. The data obtained indicate high clinical efficacy and a favorable safety profile of combination therapy with Xefocam Rapid and Xefomyelin in patients with CLBP.


  • Open Access

    Autonomic cardiovascular dysregulation and other non-motor manifestations of Parkinson’s disease

    by A. A. Pilipovich, O. V. Vorob'EVa, S. A. Makarov

    Most patients with Parkinson’s disease (PD) experience autonomic cardiovascular dysfunction (insufficiency), which, together with other nonmotor manifestations, negatively affects quality of life and disease progression.Objective: to assess the relationship between autonomic cardiovascular dysfunction and other non-motor symptoms of PD.Material and methods. A total of 252 patients with PD Hoehn and Yahr stages I–III were examined. The evaluation included: a questionnaire aimed at identifying symptoms of orthostatic intolerance (OI), orthostatic test, evaluation using the Unified Parkinson’s Disease Rating Scale (UPDRS I–IV), the Schwab and England Activities of Daily Living Scale (Sch&En), the Mini-Mental State Examination (MMSE), the Non-Motor Symptoms Questionnaire (NMSQ), the Beck Depression Inventory, the Spielberger State-Trait Anxiety Inventory, the Glasgow Dyspepsia Severity Score (GDSS), the Gastrointestinal Symptom Rating Scale (GSRS), the Bristol Stool Form Scale (BSFS), and the International Prostate Symptom Score (IPSS). A subset of patients (n=31) underwent heart rate variability (HRV) assessment.Results. Among patients with OI symptoms (35.3% of all participants) we found the worst non-motor outcomes UPDRS I (pConclusion. The data indicate that one-third of stages I–III PD patients exhibit clinical signs of autonomic dysregulation affecting the cardiovascular system, gastrointestinal tract, and bladder. These are closely associated with other non-motor symptoms of PD, forming a unified neurodegenerative process involving both central and peripheral components of the nervous system. We propose that OI symptoms may serve as clinical markers of emerging widespread autonomic failure.

  • Open Access

    Professional competencies in neurology for general practitioners in a multidisciplinary hospital

    by Artem V. Volnukhin, Irina V. Borodulina, Tatiana E. Morozova, Olga V. Vorob’oVa

    BACKGROUND: There is currently no clearly defined list of neurological diseases and conditions that fall within a general practitioner’s professional responsibilities, nor an established set of relevant knowledge and practical skills. AIM: The study aimed to determine the current professional competencies, as well as the necessary knowledge and practical skills for general practitioners in neurology for providing primary healthcare in a multidisciplinary hospital. MATERIALS AND METHODS: The study utilized the Delphi method and included 41 experts who met the inclusion criteria. RESULTS: The primary neurological competencies of a general practitioner focus on the most common nervous system disorders encountered in outpatient practice. The training should emphasize conditions as tension headache, migraine, dizziness, dorsopathy, neuropathy, chronic cerebrovascular disease (including vascular cognitive impairment), and acute cerebral circulatory failure. Required knowledge should encompass diagnosis, treatment, and prevention of these conditions. Essential practical skills include assessing motor function (coordination, muscle strength, tendon and pathological reflexes), evaluating tactile and pain sensitivity, and examining meningeal symptoms. CONCLUSION: A general practitioner’s knowledge and practical skills in neurology in outpatient settings should enable them to diagnose, treat, and prevent common nervous system diseases with stable or mild-to-moderate courses.

  • Correlation of motor symptoms and cardiovascular dysfunction in Parkinson’s disease

    by A.A. Pilipovich, O.V. Vorob’eVa, S.A. Makarov

    Objective. Assessment of cardiovascular (CV) dysfunction, its association with motor symptoms of Parkinson’s disease (PD) and dopaminergic therapy. Material and methods. The study included 252 patients with Hoehn and Yahr stage I—III PD. All patients were assessed using a survey of symptoms of orthostatic intolerance (OI), an orthostatic test, UPDRS II—IV, a Sch&En daily activity score, and a Mini-Mental State Examination (MMSE). A heart rate variability (HRV) test was performed on 31 patients and 10 control subjects of comparable age. Results. OI symptoms were detected in 35.3% of patients, orthostatic hypotension in 5.8%, and lying hypertension in 34%. The HRV indices (SDNN, TP, VLF, and LF) were decreased in all patients versus the controls (p<0.0001); no normal increase in sympathetic effects occurred with the orthostatic test. The PD stage was associated with OI symptoms (p=0.003), a decrease in the total HRV power (rS=–0.357; p=0.049), an increase in lying hypertension and heart rate, and a decrease in changes in heart rate during the orthostatic test. Patients with OI symptoms had longer PD history and worse Sch&En and UPDRS scores (hypokinesia, posture, resistance, dyskinesia scores). Significant negative correlations of HRV were identified with the same motor indices: UPDRS II and III, impaired gait, posture, stiffness, and rigidity. Resting tremor or action tremor had no association with HRV and OI. The use of dopaminergic drugs (levodopa, amantadines, dopamine receptor agonists) was associated with lower systemic blood pressure and OI symptoms but did not aggravate orthostatic responses and HRV. Conclusion. Obtained data indicate the presence in patients with the initial stages of PD of autonomic CV dysfunction, closely related to the motor (especially walking and postural balance) symptoms of PD by a single neurodegenerative process covering both central and peripheral structures of the autonomic nervous system.